NFKB1 and pulmonary fibrosis: All data revealed that MSC reverses the EMT process through blocking the activation of NF-κB and Hedgehog pathway in LPS-injured MLE-12 cells, which may provide utility value for the treatment of ALI and pulmonary fibrosis.